Heads up: some links below are affiliate links — assume any provider we list may compensate us, at no cost to you. It never buys a better score, but the providers we work with are listed first. See our affiliate disclosure.
Head-to-head
CoreAge Rx vs Next Vial
CoreAge Rx and Next Vial both offer GLP-1 telehealth, but they make different trade-offs on speed to first dose, flat pricing, access and molecule choice. Here they are side-by-side on the Rx-Readiness Score — our readiness rubric.
CoreAge Rx
Higher scoreRanked #1 · Grade A
Best for: Working moms who want a decision, not a research project — flat pricing, both semaglutide and tirzepatide, and no scheduled video visit to book around work and pickup.
Visit CoreAge RxNext Vial
Ranked #193 · Grade C
Best for: A parent weighing a year up front against paying monthly, where the gap is $1,200 and the arithmetic is verifiable.
Visit Next VialThe verdict
CoreAge Rx edges out Next Vial on the Rx-Readiness Score, 95 to 54 (A vs C). Working moms who want a decision, not a research project — flat pricing, both semaglutide and tirzepatide, and no scheduled video visit to book around work and pickup.
Next Vial is still a genuine option — the spread here is the largest on the page and it is honestly stated: $2,388 a year paying monthly against $1,188 on the twelve-month plan, a difference of $1,200. Every division checks out to the dollar, and semaglutide and tirzepatide cost the same. The one thing that does not fit is the headline on that same page — "as low as $249.97/Month" — which is higher than every plan the selector offers. Weigh the six readiness factors below against your own priorities.
Side-by-side on the six factors
Both providers scored on the same readiness rubric — the higher side on each factor is marked. See the methodology.
Price, access & features
| Detail | CoreAge Rx | Next Vial |
|---|---|---|
| Rx-Readiness Score | 95/100 · A | 54/100 · C |
| Overall rank | #1 | #193 |
| Semaglutide | $99/mo | $199/mo month to month |
| Tirzepatide | $149/mo | $199/mo month to month |
| Coverage | All 50 states | Not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
CoreAge Rx
Ranked #1 · Grade A
What we like
- Flat monthly price that stays put through titration — no dose-scaling surprise on your busiest month
- Both compounded semaglutide and tirzepatide on one plan, so you're not re-signing to switch
- Async, no-video intake and all-50-states coverage — start it during a lunch break
The caveats
- Not the rock-bottom sticker price — a couple of teaser tiers elsewhere start lower
- Compounded only — no FDA-approved brand option
- General metabolic program, not a boutique concierge service
Next Vial
Ranked #193 · Grade C
What we like
- A real month-to-month option at $199, so the plan is a choice rather than the only route
- Every plan total divides exactly: $507, $894, $1,188, $477, $834 and $948
- The twelve-month plan halves the annual cost, from $2,388 to $1,188
The caveats
- The headline says "as low as $249.97/Month", above every price the selector offers
- The $99 rate requires $1,188 up front
- The microdose route has no one-month option — three months minimum
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Rx-Readiness Score. Pricing, states and verification reflect each provider's public disclosures at last review; the Rx-Readiness Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.
More head-to-heads
Keep comparing CoreAge Rx and Next Vial against other providers on our shortlist.
Or browse the full comparison hub.